澳大利亚科学家基于特定基因突变开发了针对骨髓纤维化（一种罕见血癌）的靶向免疫疗法。 Australian scientists developed a targeted immunotherapy for myelofibrosis, a rare blood cancer, based on specific gene mutations.

澳大利亚研究人员开发了一种针对骨髓纤维化的新靶向疗法，这是一种罕见的血癌，会导致疲劳和脾脏肿大。 Australian researchers have developed a new targeted therapy for myelofibrosis, a rare blood cancer causing fatigue and spleen enlargement. 该研究在《血液》中发表,确定了基于1型和2型卡列硫素突变的两种不同免疫疗法目标,使免疫系统能够在保持健康组织的同时精确地攻击异常细胞。 Published in Blood, the study identifies two distinct targets for immunotherapy based on Type 1 and Type 2 calreticulin mutations, enabling the immune system to precisely attack abnormal cells while sparing healthy tissue. 这一精确方法由Daniel Thomas和SAHMRI的Angel Lopez牵头,标志着治疗战略中世界第一的区别,从症状管理转向针对疾病的治疗。 This precision approach, led by Daniel Thomas and Angel Lopez at SAHMRI, marks a world-first distinction in treatment strategies and represents a shift from symptom management to disease-targeted therapy. 虽然人类审判尚未结束,但调查结果为更有效、更长久的治疗带来了希望。 While human trials are still pending, the findings offer hope for more effective, long-lasting treatments.